Low Expression of IncRNA-GAS5 Is Implicated in Human Primary Varicose Great Saphenous Veins

Li Li1,2,3,4☯, Xiang Li5☯, Erlinda The1,2,6☯, Li-Jie Wang1,6☯, Tian-You Yuan1,6, Shi-Yi Wang1,6, Jing Feng6, Jing Wang6, Yuan Liu1,6, Ya-Han Wu1,2,6, Xiu-E Ma1,6, Jin Ge7, Ying-Yu Cui2,3,4*, Xiao-Yan Jiang2,3,4*

1 Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai 200120, China, 2 Key Laboratory of Arrhythmias of the Ministry of Education of China, Tongji University School of Medicine, Shanghai 200092, China, 3 Institute of Medical Genetics, Tongji University, Shanghai 200092, China, 4 Department of Pathology and Pathophysiology, Tongji University School of Medicine, Shanghai 200092, China, 5 Department of Cardiology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China, 6 Department of Cardiovascular Surgery, East Hospital, Tongji University School of Medicine, Shanghai 200120, China, 7 Department of Vascular Surgery, East Hospital, Tongji University School of Medicine, Shanghai 200120, China

☯ These authors contributed equally to this work.
* xiaoyanjiang001@163.com (X-YJ); yycui@tongji.edu.cn (Y-YC)

Abstract

The cellular mechanisms of primary varicose great saphenous veins (GSVs) involve inflammation, apoptosis, and proliferation of local cells and extracellular matrix degradation. Long non-coding RNAs (lncRNAs) play important roles in these cellular processes; however, which and how lncRNAs related to these mechanisms take effect on GSVs remain unclear. By screening lncRNAs that might experience changes in GSV varicosities, we selected the lower expressed lncRNA-GAS5 (growth arrest specific transcript 5) for functional assessments. Silencing of lncRNA-GAS5 promoted cell proliferation and migration, and cell cycle of the human saphenous vein smooth muscle cells (HSVSMCs), whereas overexpressing it inhibited these cellular behaviors and reduced apoptosis of HSVSMCs. RNA pull-down experiment revealed a direct binding of lncRNA-GAS5 to a Ca2+-dependent RNA-binding protein, Annexin A2. Further experiments showed that silencing of Annexin A2 reduced the proliferation of HSVSMCs while overexpression of Annexin A2 increased the proliferation. Thus, the low expression of IncRNA-GAS5 may facilitate HSVSMCs proliferation and migration through Annexin A2 and thereby the pathogenesis of GSV varicosities.

Introduction

Varicose veins, with leg edema, chronic and disabling venous ulceration, affect 25% adult population and lead to considerable morbidity and cost of health service resources, while great
saphenous veins (GSVs) or saphenofemoral junction account for about 70% of varicose veins [1–3]. The pathogenesis processes of GSVs are associated with leukocyte diapedesis and local inflammation, smooth muscle cell (SMC) apoptosis and proliferation, extracellular matrix degradation, and endothelial cell injury, which result in venous valvular dysfunctions that cause blood reflux, vein wall tension increase, vein wall dilation and tissue remodeling [3,4,5]. However, the molecular pathways involved in these processes remain elusive.

Some protein molecules such as HIF-1 alpha [6], Janus-kinase/signal transducers [7], poly ADP ribose polymerase (PARP) [8], and intercellular adhesion molecule 1 [9] were involved in the pathogenesis processes of GSVs. Recently, using genome-wide screening and subsequently q-RT-PCR validations, we found six lncRNAs (AF119885, AK021444, NR_027830, G36810, NR_027927, and uc.345-) aberrantly expressed in GSVs, suggesting lncRNAs might be involved in the pathogenesis processes of GSVs [10]. In the present study, we selected lncRNAs relating to cell proliferation, growth, apoptosis, tumor genesis and vascular disease in lncRNAdb database, which provides detailed lncRNA information, including sequences, functions, expressions, associated proteins and cellular locations [11], to observe which and how long non-coding RNAs (lncRNAs) take effects on the pathology of GSVs. This study helps identify novel molecular mechanisms involved in the pathogenesis of GSVs.

**Materials and Methods**

**Patients and tissue samples**

Fifty-three samples of human primary great saphenous veins (GSVs) were retrieved from 53 patients (25 males, 28 females) who were undergoing GSVs varicose vein excision in Shanghai East Hospital, Tongji University School of Medicine, China. The diagnosis of primary varicose GSVs was based on the clinical signs and duplex ultrasound scanning. All patients were characterized as having primary varicocities. The exclusion criteria, classification criteria, and ultrasound scanning assessment were described in details previously [10]. According to clinical, etiological, anatomical and pathological elements classification system (CEAP) [12,13], the subjects were class 4–6 GSVs, with 51 of the subjects in class 4, one in class 5 and one in class 6. The clinical demographic characteristics and clinical risk factors of the subjects are given in Table 1.

The methods to prepare paired tissues were described in detail previously [10]. The tissues were then snap-frozen into liquid nitrogen immediately after resection for later RNA extraction. A fraction of NV tissues were used to isolate and culture the human saphenous vein smooth muscle cells (HSVSMCs). Written informed consent was obtained from all participants. The study was approved by the Human Ethics Committee of Shanghai East Hospital, Tongji University School of Medicine (NO.: 2011-DF-53).

**Screening of differentially expressed lncRNAs**

Long noncoding RNA database (lncRNAdb,[http://lncrnadb.com/](http://lncrnadb.com/)) is a database providing comprehensive annotations of eukaryotic long non-coding RNAs. We analyzed the structure, expression levels and functions of all the 111 human species lncRNAs in the lncRNAdb in August, 2011 and filtered the candidate lncRNAs which may be related to the pathophysiological processes of primary varicose veins using the key words such as cell proliferation, growth, apoptosis, tumor genesis and vascular disease. Each full sequence of the filtered candidate lncRNAs was searched by UCSC Genome Browser Home and inputed into the Roche Applied Science: Universal Probe Library System—Assay Design Center ([https://www.roche-applied-science.com](https://www.roche-applied-science.com)) [14] to design proper probes and primers for the Q-RT-PCR.
Total RNA was extracted from frozen vein specimens of 53 pairs of samples using TRIzol reagent (Invitrogen Life Technologies) and then reverse transcribed using a PrimeScript RT Reagent Kit (Takara) according to the manufacturer’s instructions. LncRNA expression in VV and paired NV tissues was measured by Q-RT-PCR using Power SYBR Green PCR Master Mix (Applied Biosystems) on the ABI PRISM 7900 Sequence Detection System (SDS) instrument which were described in detail previously [10]. All experiments were performed in triplicate.

**Isolation and culture of the human saphenous vein smooth muscle cells (HSVSMCs)**

The HSVSMCs were successfully isolated by tissue explant outgrowth [15] (S2 Fig.). The human saphenous vein tissues were put into the high glucose DMEM (Hyclone) containing 10% FBS (GIBCO) and 100X Penicillin-Streptomycin (GIBCO) immediately after resection from the patients in the operating room. The tissues were transported into the laboratory on the ice, and were dissected in the super clean bench. The tunica media were stripped and cut into pieces (1mm³). The tissues pieces were mixed with FBS and evenly attached to the bottom of the 25 cm² flask with 1cm intervals. The flasks were incubated at 37°C in a 5% CO₂ humidified incubator and cannot be moved in the first 3 days, then the culture medium were changed every 3 days. After one month of cultivation, HSVSMCs were almost growing a confluent layer (S2 Fig.), and then were subcultured. HSVSMCs of the fifth generation were identified by staining with immunofluorescence (S3 Fig.). The growth characteristics of HSVSMCs were studied. The cell survival rate was 96.5% tested by the Trypan Blue. The growth curve of HSVSMCs (S4 Fig.) was shown according to the cytometry. The HSVSMCs proliferation activity (S5 Fig.) was detected by cell counting kit-8 (CCK-8) (Beyotime, Jiangsu, China) [16], its growth increased significantly during the 3–5 days, and indicated a proliferative time of HSVSMCs growth. The HSVSMCs migration activity detected by scratching. The 5–12 passages HSVSMCs were used for functional study.

| Table 1. The clinical information of 53 patients involved in the study. |
|-------------------------------------------------|----------|----------|----------|
| Patients number of gender                        | Male     | Female   | Total    |
| 25                                               | 28       | 53       |
| Age±SD (years)                                   | 56.5±10.0| 56.1±7.7 | 56.3±8.7 |
| Course of CVI (years)                            | 11.2±7.4 | 8.9±8.2  | 10.0±7.8 |
| Previous chronic illnesses                       |          |          |          |
| Hypertension                                     | 9        | 6        | 15       |
| Parkinson                                        | 1        | 1        | 2        |
| Gastric ulcer                                    | 0        | 1        | 1        |
| Diabetes                                         | 1        | 0        | 1        |
| left limb                                        | 11       | 6        | 17       |
| right limb                                       | 12       | 13       | 25       |
| double limbs                                     | 2        | 9        | 11       |
| CEAP grade                                       |          |          |          |
| Class 6                                          | 1        | 0        | 1        |
| Class 5                                          | 1        | 0        | 1        |
| Limbs of Surgery                                 |          |          |          |
| Class 4                                          | 23       | 28       | 51       |
| Specialist physic examination                    |          |          |          |
| Perthes test (-)                                 | 25       | 28       | 53       |
| Duplex ultrasound scanning                       |          |          |          |
| Deep venous thrombosis                           | 0        | 2        | 2        |
| Valve insufficiency of GSV                       | 25       | 28       | 53       |
| Reflux of GSV                                    | 25       | 28       | 53       |

DOI:10.1371/journal.pone.0120550.t001
Proliferation, migration, apoptosis and cell cycle of HSVSMCs affected by lncRNA-GAS5

Three different lncRNA-GAS5 siRNAs (small interfering RNAs) were designed by Shanghai GenePharma Company according to the full sequence of lncRNA-GAS5 (NR_002578.2) in NCBI. The siRNAs ID were GAS5-homo-385, GAS5-homo-204, and GAS5-homo-151. Negative-control and positive-control siRNA were also purchased from Shanghai GenePharma Company. The siRNAs were transfected into HSVSMCs according to the manufacturer’s instructions by Lipofectamin RNAiMAX (Invitrogen). The full sequence of lncRNA-GAS5 (631nt, excluding the 20nt polyA) were cloned into the expression vector pCMV-N-Flag and transfected into HSVSMCs according to the manufacturer’s instructions by Lipofectamine 2000 (Invitrogen). The transfection efficiencies (fluorescently labelled cells after 48 hours) were 70–80%. The analysis of specific silencing or overexpression of lncRNA-GAS5 expression was carried out after 48 hours, using Q-RT-PCR. The lncRNA-GAS5 primers were human-GAS5-F (5′ to 3′): cttgcctggaccagcttaat; human-GAS5-R (5′ to 3′): caagccgactctccatacct.

To assess the proliferation, migration, apoptosis and cell cycle of HSVSMCs when silencing or overexpression of lncRNA-GAS5. The proliferation abilities of HSVSMCs were measured using CCK-8 kit (Beyotime, Jiangsu, China) and EDU kit (RiboBio, Guangzhou, China) [17] according to the manufacturer’s instructions. As a proliferation inhibitor, rapamycin was used to inhibit the proliferation abilities of normal HSVSMCs to make the proliferation abilities changes more significant [18]. The concentration of rapamycin used in the study were 0,100 and 200ng/ml, and the action time of rapamycin were 48 hours. Cell scratch test and Transwell (BD) were used to measure the migration abilities of HSVSMCs. After transfected by lncRNA-GAS5 siRNA for 48 hours, the HSVSMCs were passage into the Transwell Inserts. Then 4 hours, 7 hours, 10 hours later, the migration HSVSMCs were photographed and counted, respectively. The migration abilities of HSVSMCs were reflected indirectly by the new migration cells counting with Transwell. The apoptosis of HSVSMCs were measured by Flow Cytometry using Annexin V-FITC apoptosis kit (Beyotime, Jiangsu, China) [19] according to the manufacturer’s instructions. Moreover, p27-kip1 and p21-cip1, two negative regulatory factors of Cyclin Dependent Kinase, which could inhibite the process of cell cycle acting as antagonist of Cyclin [20], were choosen to reflect cell cycle changes indirectly. The p27-kip1 and p21-cip1 mRNA expression level were measured by Q-RT-PCR.

RNA pulldown assay and matrix-assisted laser desorption/ ionization time of flight mass spectrometry (MALDI-TOF-MS)

RNA pull-down assay [21] was used to find the proteins bonding to lncRNA-GAS5 directly. Briefly, the biotin-labeled full length lncRNA-GAS5 RNA and antisense lncRNA-GAS5 RNA were transcribed in vitro with the Biotin RNA Labeling Mix (Roche) and T7 RNA polymerase (Roche), treated with RNase-free DNase I (Roche), recycled with QIA quick Nucleotide Removal Kit(Qiagen) and purified with the RNeasy Mini Kit (Qiagen). HSVSMCs proteins were extracted using the RIPA (Beyotime) and protease inhibitor cocktail (Roche). One milligram of HSVSMCs proteins was then mixed with 3ug of biotin-labeled lncRNA-GAS5 RNAs incubated at 4C for 1 hour. Thirty microliters of washed streptavidin agarose beads (Invitrogen) were washed by 100ul RIPA buffer(Sigma), then added to each binding reaction and further incubated at room temperature for 1 hour. Beads were washed by DEPC-treated PBS briefly three times and boiled in sodium dodecyl sulfate buffer at 100C for 10 minutes, and the retrieved protein was visualized by an SDS-PAGE gel electrophoresis (Beyotime, Jiangsu, China) [22] and silver staining technique (Beyotime, Jiangsu, China) [23]. The Specific differently stained
gel pieces were cut down and Proteins in gel pieces were identified by MALDI-TOF-MS with the help of Shanghai Boyuanbio Company.

Statistical analysis
All the statistical analyses were performed using SPSS version 18.0 software (SPSS). For Q-RT-PCR analysis, all samples were normalized to GAPDH. The mean value in each triplicate was used to calculate relative IncRNAs concentrations ($\Delta C_t = C_t \_{\text{mean IncRNAs}} - C_t \_{\text{mean GAPDH}}$). Expression fold changes were calculated using $2^{-\Delta \Delta C_t}$ methods. For comparisons, independent-samples Student’s t-tests and one-way analysis of variance were performed. The value of $P < 0.05$ was considered as statistically significant.

Results
Differential expression of IncRNAs in VVs and NVs
The cellular mechanisms of GSVs include inflammation, apoptosis, and proliferation of local cells and extracellular matrix degradation. Therefore, we focused on the IncRNAs relating to these mechanisms and selected 39 candidate IncRNAs from IncRNAdb. The names, sequence lengths and related functions of these IncRNAs were shown in S1 Table. After exclusion of 17 IncRNAs for invalid primers, 22 IncRNAs were selected, and their IncRNAs names, probe numbers and primer sequences were shown in S2 Table. Seven IncRNAs were excluded for further analysis due to very low relative IncRNAs expressions. Finally, the expression differences of 15 IncRNAs between the varicose GSVs and control veins were measured by Q-RT-PCR (S1 Fig., Fig. 1).

The aberrant expressions ($\Delta \Delta C_t$ value) of the 15 IncRNAs were shown in Fig. 1. With the increase of tested sample pairs, IncRNA-21A (up to 25) and IncRNA-GAS5 (up to 53, Fig. 2) showed significant different expressions. Since the knockdown and transfection of which was suitable to design, IncRNA-GAS5, instead of IncRNA-21A, were further selected to assess functional mechanism by silencing and overexpressing IncRNAs in vitro.

IncRNA-GAS5 regulates the proliferation and migration of HSVSMCs
The proliferation and migration of smooth muscle cells are important pathological processes of GSA. Therefore, we observed whether IncRNA-GAS5 influence these processes. The expression level of IncRNA-GAS5 was effectively changed by transfecting the siRNAs and overexpression plasmid into the HSVSMCs (Fig. 3). When the siRNA was transfected at the concentration of 80 pmol for 48 hours, the expression level of IncRNA-GAS5 was reduced more than 70%. When the overexpression plasmid was transfected at the concentration of 2ug/ml, the expression level of IncRNA-GAS5 was increased more than one thousand times after 48 hours overexpressing. The proliferation and migration of HSVSMCs were affected by silencing or overexpressing IncRNA-GAS5.

Down-regulation of IncRNA-GAS5 has been proven to inhibit proliferation produced by rapamycin in leukemic and primary human T cells [24], which indicates IncRNA-Ga5 regulates cell proliferation. We showed that IncRNA-GAS5 affected the proliferation of HSVSMCs (Fig. 4). Knockdown of IncRNA-GAS5 increased the proliferation of HSVSMCs by CCK-8 and EDU assay (Fig. 4A, C, E). Conversely, overexpression of IncRNA-GAS5 inhibited the proliferation of HSVSMCs (Fig. 4B, D). The migrations of HSVSMCs were measured by Cell scratch test and Transwell. Fig. 5A showed the HSVSMCs which have the best migration abilities in the first 24 hours. Down-expression of IncRNA-GAS5 promotes HSVSMCs migration and increases the number of new migration cells (Fig. 5B, C).
LncRNA-GAS5 affects the apoptosis and cell cycle of HSVSMCs

LncRNA-GAS5 has been proven to be necessary and sufficient for normal growth arrest in T-cell lines and human peripheral blood T-cells by controlling cell cycle and cell apoptosis [25]. Overexpression of GAS5 extends cell cycle and promotes apoptosis of these cells while down-regulation of lncRNA-GAS5 maintains a more rapid cell cycle and inhibits apoptosis [25]. Similar effects might exist in smooth muscle cells. To test this hypothesis, we used p27-kip1 and p21-cip1 to detect cell cycle changes [26]. We found that the expression of p27-kip1 and p21-cip1 was reduced to 24.9% and 37.2%, respectively with knockdown of lncRNA-GAS5 (Fig. 6A). The expression of p27-kip1 and p21-cip1 increased 2.81 and 2.51 times with overexpression of lncRNA-GAS5 (Fig. 6B), compared with controls. Although down-regulation of lncRNA-GAS5 did not affect the apoptosis of HSVSMCs (data not show), overexpression of lncRNA-GAS5 decreased the early apoptosis of the HSVSMCs (Fig. 6C). These results indicated that lncRNA-GAS5 may play different role in different cells and the expression patterns of lncRNAs are tissue- and cell-specific.

Fig 1. The aberrant expression of the 15 lncRNAs by Q-RT-PCR with the increase of tested sample pairs. After exclusion of 17 lncRNAs for invalid primers and 7 lncRNAs for very low relative lncRNAs expressions, the expression differences between the varicose GSVs and control veins of 15 lncRNAs were measured by Q-RT-PCR. ΔΔCT show the actual relative expression fold change as $2^{-\Delta\Delta CT}$. The positive value means down-regulated expression of the lncRNA between the varicose GSVs and control veins, conversely, the negative value means up-regulated expression of the lncRNA between the varicose GSVs and control veins. *: P < 0.05.

doi:10.1371/journal.pone.0120550.g001

IncRNA-GAS5 affects the apoptosis and cell cycle of HSVSMCs

LncRNA-GAS5 has been proven to be necessary and sufficient for normal growth arrest in T-cell lines and human peripheral blood T-cells by controlling cell cycle and cell apoptosis [25]. Overexpression of GAS5 extends cell cycle and promotes apoptosis of these cells while down-regulation of lncRNA-GAS5 maintains a more rapid cell cycle and inhibits apoptosis [25]. Similar effects might exist in smooth muscle cells. To test this hypothesis, we used p27-kip1 and p21-cip1 to detect cell cycle changes [26]. We found that the expression of p27-kip1 and p21-cip1 was reduced to 24.9% and 37.2%, respectively with knockdown of lncRNA-GAS5 (Fig. 6A). The expression of p27-kip1 and p21-cip1 increased 2.81 and 2.51 times with overexpression of lncRNA-GAS5 (Fig. 6B), compared with controls. Although down-regulation of lncRNA-GAS5 did not affect the apoptosis of HSVSMCs (data not show), overexpression of lncRNA-GAS5 decreased the early apoptosis of the HSVSMCs (Fig. 6C). These results indicated that lncRNA-GAS5 may play different role in different cells and the expression patterns of lncRNAs are tissue- and cell-specific.
Annexin A2 mediates the effects of lncRNA-GAS5 in HSVSMCs

Recent studies have identified a variety of lncRNAs that bind to a specific protein to modify the activity, structure, and localization of the protein [27]. Using RNA Pulldown assay, SDS-PAGE gel electrophoresis, Silver stain and MALDI-TOF-MS, we identified that PRO2044 [Homo sapiens] (ID: gi|6650826), Chain A of Solution Structure Of Human Coactosin Like Protein D123n (ID: gi|71041611), and Annexin A2 isoform 2 [Homo sapiens] (ID: gi|4757756) were directly bond to lncRNA-GAS5, with Annexin A2 isoform 2 selected for further mechanism exploration since the binding effects of Annexin A2 isoform 2-GAS5 (Fig. 7A) were repeated. Silencing or overexpressing reduce the expression of Annexin A2 more than 90% and increased more than 40 times (Fig. 7B, C). Knockdown of Annexin A2 inhibited the proliferation of HSVSMCs, while its overexpression increased (Fig. 7D). Silencing Annexin A2 followed by silencing lncRNA-GAS5 reduce HSVSMCs proliferation compared to silencing lncRNA-GAS5 only while overexpressing Annexin A2 followed by silencing lncRNA-GAS5 increase its proliferation (Fig. 7E). These findings suggest that Annexin A2 mediated lncRNA-GAS5 inhibition facilitates HSVSMCs proliferation and migration and hence the pathogenesis of GSV varicosities. However, the exact sites of lncRNA-GAS5 that binds to Annexin A2 and the regulating effects of lncRNA-GAS5 to Annexin A2 need to be further investigated.

Discussion

In this study, we identified a low expression of lncRNA, lncRNA-GAS5, in human primary varicose great saphenous veins, which facilitates the proliferation and migration of HSVSMCs.
through the mediation of Annexin A2. To the best of our knowledge, we report for the first time that lncRNA-GAS5 is implicated in the pathogenesis of GSVs.

GAS5 is a tumor suppressor gene encoding 10 box C/D snoRNAs within 11 introns. Although different patterns of alternate splicing transcripts of GAS5 is ubiquitously expressed,
they are unstable during even relatively short periods of evolution in proliferating cells for nonsense-mediated RNA decay [28]. Therefore, any important biological activities of GAS5 must be mediated by the introns, which encode multiple small nucleolar RNAs. The functions of lncRNA-GAS5 include arresting of fibroblast cell growth or inhibition of translation by rapamycin as a proliferation inhibitor.

**Fig 4.** lncRNA-GAS5 affects the proliferation of HSVSMCs. As a proliferation inhibitor, rapamycin was used to inhibit the proliferation abilities of normal HSVSMCs to make the proliferation abilities changes more significant. The concentration of rapamycin used in the study were 0, 100 and 200ng/ml, and the action time of rapamycin were 48 hours. 

**A:** Knockdown of lncRNA-GAS5 increased the proliferation of HSVSMCs by CCK-8 assay. Values are mean±SE, N = 3; *, P < 0.05. **B:** Overexpression of lncRNA-GAS5 inhibited the proliferation of HSVSMCs by CCK-8 assay. Values are mean±SE, N = 3; *, P < 0.05. 

**C:** Knockdown of lncRNA-GAS5 increased the proliferation of HSVSMCs by EDU assay. Values are mean±SE, N > 30; *, P < 0.05. **D:** Overexpression of lncRNA-GAS5 inhibited the proliferation of HSVSMCs by EDU assay. Values are mean±SE, N > 30; *, P < 0.05. 

**E:** The new proliferation HSVSMCs stained by EDU kit. Knockdown of lncRNA-GAS5 increased the proliferation of HSVSMCs. Optical microscope images under 100x magnification, Scale bars = 100um.

doi:10.1371/journal.pone.0120550.g004
Fig 5. IncRNA-GAS5 affects the migration of HSVSMCs. Cell scratch test and Transwell were used to measure the migration abilities of HSVSMCs. NC = Negative control group, only control siRNA transfected;
cycloheximide, pactamycin, or rapamycin, blocking the upregulation of gene expression by activated glucocorticoid receptor, and controlling cell apoptosis. Therefore, lncRNA-GAS5 may play an important role in the progression of some types of cancer [22,29]. The proliferating effects of lncRNA-GAS5 remain to be elucidated. Recent studies using MOLT-4 T-leukaemic cells, Mourtada-Maarabouni et al. found that lncRNA-GAS5 specific siRNAs protect the proliferation of MOLT-4 T-leukaemic cells from the inhibition of rapalogues through mTOR (mammalian target of rapamycin) pathway [24]. We also identified the mTOR mediated proliferation effects of lncRNA-GAS5 in HSVSMCs, suggesting that lncRNA-GAS5 may regulate the proliferation of different cells.

Overexpression of lncRNA-GAS5 leads to both an increase in apoptosis and a reduction in the progression rates of different cancer cell lines by inhibiting cell cycle dependently or independently. Consistently, downregulation of lncRNA-GAS5 inhibits apoptosis of cancer cells and maintains a more rapid cell cycle [30]. In addition, lncRNA-GAS5 was observed to play a similar effect in normal growth arrest in both T-cell lines and non-transformed lymphocytes [25]. In this study, we found that lncRNA-GAS5 silencing facilitates a more rapid cell cycle of normal saphenous vein smooth muscle cells, while its overexpression delays cell cycle and reduces apoptosis of the cells. The similar cell-cycle effects of lncRNA-GAS5 on cancer cells, lymphocytes, and vein smooth muscle cells may reflect its general regulatory effects, while the different effects of lncRNA-GAS5 on apoptosis in other cancer cells and our normal saphenous vein smooth muscle cells may reflect a tissue and disease specific roles.

The molecules binding to lncRNA-GAS5 that mediate cell proliferation, migration, arrest, and apoptosis remain to be identified. Recently, Kino et al. found that lncRNA-GAS5 binds to the DNA-binding domain of the glucocorticoid receptor (GR) through nucleotides 400 to 598 to block the upregulation of gene expression by activated GR [29]. In this study, we are the first to identify a Ca^{2+}-dependent phospholipid-binding protein Annexin A2, which directly bond to lncRNA-GAS5. Annexin A2 has a unique N-terminus tail domain that contains a nuclear export signal (NES) as well as multiple phosphorylation sites. Annexin A2 is involved in mammalian cell cycle regulation [33], and its levels are enhanced in many cancers [34]. Furthermore, Annexin A2 is a novel RNA-binding protein, and binding studies confirmed a direct interaction between Annexin A2 and c-myc mRNA [35]. In the present study, we observed a direct interaction between Annexin A2 and lncRNA-GAS5, which regulate the proliferation, migration, and cell cycle of HSVSMCs. However, the binding site and the mechanisms of the binding effects need to be further investigated.

The strength of this study should be addressed. Paired tissues were used to observe the expression differences between lesion and adjacent normal tissues. Unlike studies in which saphenous veins from healthy subjects were selected as controls, this design was not subject to genetic and environmental confounders. In addition, we focused studied samples on valve

---

GASS(−) = lncRNA-GAS5 knockdown group transfected with silence siRNA. A: Cell scratch test was used to measure the migration abilities of HSVSMCs. The results showed that the HSVSMCs have the best migration abilities in the first 24 hours. Values are means±SE, N = 4. B: The migration abilities of HSVSMCs measured by Transwell. After transfected by lncRNA-GAS5 siRNA for 48 hours, the HSVSMCs were passage into the Transwell Inserts. Then 4 hours, 7 hours, 10 hours later, the migration HSVSMCs were photographed and counted, respectively. Knockdown of lncRNA-GAS5 expression promotes migration of HSVSMCs. Optical microscope images under 200x magnification. C: The migration abilities of HSVSMCs were reflected indirectly by the new migration cells counting with Transwell. Silencing of lncRNA-GAS5 expression increases migration ability of HSVSMCs. Values are means±SE, N = 10; *, P < 0.05.

doi:10.1371/journal.pone.0120550.g005
insufficiency and reflux of GSVs, which diminished the heterogeneity of the studied phenotype, and reduced the likelihood of false positives discoveries. The limitations of this study should also be addressed. The detailed regulation mechanisms of cell growth, proliferation, and migration are pending for further studies and the binding site of Annexin A2 with lncRNA-GAS5 also needs to be identified.

Fig 6. IncRNA-GAS5 affects the cell cycle and apoptosis of HSVSMCs. As Negative regulatory factors of Cyclin Dependent Kinase, p27-kip1 and p21-cip1 can delay the process of cell cycle acting as antagonist to Cyclin. Therefore, they were chosen to reflected cell cycle changes indirectly. A: The p27-kip1 and p21-cip1 mRNA expression levels were measured by Q-RT-PCR with knockdown of lncRNA-GAS5 in HSVSMCs. Values are mean±SE, N = 3; *, P < 0.05. B: The p27-kip1 and p21-cip1 mRNA expression level were measured by Q-RT-PCR with overexpression of lncRNA-GAS5 in HSVSMCs. Values are mean±SE, N = 3; *, P < 0.05. C: The apoptosis of HSVSMCs were measured by Flow Cytometry using Annexin V-FITC apoptosis kit. The result shows that the HSVSMCs in early apoptosis decreased with overexpression of lncRNA-GAS5. N = 3; *, P < 0.05.

doi:10.1371/journal.pone.0120550.g006
Fig 7. The effects of lncRNA-GAS5 mediated by Annexin A2. A2 = Annexin A2; Mock = control group, only empty plasmid transfected; NC = Negative control group, only control siRNA transfected; A2 siRNA = Annexin A2 knockdown group transfected with silence siRNA; A2 over = Annexin A2 overexpression group transfected with Annexin A2 expression plasmid; GAS5 down = lncRNA-GAS5 knockdown group transfected with silence siRNA. A: Silver stains for protein gels obtained by lncRNA-GAS5 RNA Pulldown. Bio-GAS5 (sense); Bio-GAS5 (antisense); GAS5 (sense); negative control groups. The GAS5 specific-binding protein gels (in Red box) was identified by MALDI-TOF-MS. Results show that Annexin A2 isoform 2 is a direct binding protein to lncRNA-GAS5. N = 2. B: The Annexin A2 expression level was knockdowned in HSVSMCs effectively by siRNA. Values are mean \pm SE, N = 3; *, P < 0.05. C: The Annexin A2 expression level was over-expressed by constructing and transfecting expression plasmid. Values are mean \pm SE, N = 3; *, P < 0.05. D: The proliferation abilities of HSVSMCs were reflected indirectly by the OD450 values measured using CCK-8 kit when Annexin A2 expression level were knockdowned or over-expressed in HSVSMCs. Values are mean \pm SE, N = 3; *, P < 0.05. E: The proliferation abilities of HSVSMCs were reflected indirectly by the OD450 values measured using CCK-8 kit when Annexin A2 and lncRNA-GAS5 expression levels were knockdowned or over-expressed simultaneously in HSVSMCs. Firstly Annexin A2 siRNA or expression plasmid were transfected into the HSVSMCs, six hours later, the cell culture medium were changed and then lncRNA-GAS5 siRNA were transfected into the HSVSMCs. Another 48 hours later, the OD450 values were measured by CCK-8 kit. Values are mean \pm SE, N = 3; *, P < 0.05.

doi:10.1371/journal.pone.0120550.g007
In sum, we identified a lncRNA, IncRNA-GAS5, low-expression of which in GSVs facilitates HSVSMCs proliferation and migration through Annexin A2. The finding provides novel insights into the physiology of IncRNAs and the pathogenesis of varicose veins.

Supporting Information

S1 Fig. The aberrant expression of the 15 lncRNAs by Q-RT-PCR with about 10 sample pairs. After exclusion of 17 lncRNAs for invalid primers and 7 lncRNAs for very low relative IncRNAs expressions, the expression differences between the varicose GSVs and control veins of 15 lncRNAs were measured by Q-RT-PCR with 10 sample pairs (except for seven sample pairs of LOC285194). \( \Delta\Delta CT \) show the actual relative expression fold change as \( 2^{-\Delta\Delta CT} \). Values are mean±SE. The positive value means down-regulated expression of the lncRNA between the varicose GSVs and control veins, conversely, the negative value means up-regulated expression of the lncRNA between the varicose GSVs and control veins. *: P<0.05.

S2 Fig. The human saphenous vein smooth muscle cells (HSVSMCs) isolated by tissue explant outgrowth. HSVSMCs were seen around the human saphenous vein smooth muscle tissue pieces after the tissue pieces adherence one week. After one month of cultivation, HSVSMCs were almost growing a confluent layer, and then were subcultured. A: Optical microscope images show HSVSMCs growth for one month under 40x magnification, Scale bars = 50um; B: Optical microscope images show HSVSMCs growth for one month under 100x magnification, Scale bars = 500um.

S3 Fig. The human saphenous vein smooth muscle cells (HSVSMCs) were identified by staining with immunofluorescence. HSVSMCs of the fifth generation were stained with primary antibodies \( \alpha \)-actin (Sigma), fluorescent secondary antibody (Sigma) staining cytoplasm, and Hochest33342 (Beyotime) staining nucleus. A: 200x magnification; B: 400x magnification.

S4 Fig. The growth curve of HSVSMCs was drawn according to the cytometry. The HSVSMCs grew into the exponential phase, its growth increased significantly during the 3–5 days. Values are mean±SE, N = 6.

S5 Fig. The HSVSMCs proliferation activity detected by cell counting kit-8 (CCK-8). OD450 nm absorbance values of HSVSMCs were detected by Microplate System, which indirectly show the proliferation and survival ability of HSVSMCs. The HSVSMCs proliferation activity was detected by cell counting kit-8 (CCK-8, Beyotime), its growth increased significantly during the 3–5 days, and indicated a proliferative time of HSVSMCs growth. Values are mean ±SD, N = 5.

S1 Table. The information of 39 candidate lncRNAs related to the key words in the study.

S2 Table. The probes and primers of the 22 lncRNAs validated by Q-RT-PCR in the study.

Acknowledgments

We would like to thank all the donors who participated in this program.
Author Contributions
Conceived and designed the experiments: XYJ XL. Performed the experiments: XL JW ET LW TYY. Analyzed the data: XL. Contributed reagents/materials/analysis tools: LL YC JG SW JF YL YW XM. Wrote the paper: XYJ XL.

References

1. Fowkes FG, Lee AJ, Evans CJ, Allan PL, Bradbury AW, Ruckley CV. Lifestyle risk factors for lower limb venous reflux in the general population: Edinburgh Vein Study. Int J Epidemiol. 2001; 30: 846–852. PMID: 11511615

2. van Groenendael L, van der Vliet JA, Flinkenflögel L, Roovers EA, van Sterkenburg SM, Reijnen MM. Treatment of recurrent varicose veins of the great saphenous vein by conventional surgery and endovenous laser ablation. J Vasc Surg. 2009; 50: 1106–1113. doi: 10.1016/j.jvs.2009.06.057 PMID: 19878788

3. Lim C, Davies A. Pathogenesis of primary varicose veins. Br J Surg. 2009; 96: 1231–1242. doi: 10.1002/bjs.6798 PMID: 19487681

4. Raffetto J, Khalil R. Mechanisms of varicose vein formation: valve dysfunction and wall dilation. Phlebology. 2008; 23: 85–98. doi: 10.1258/phleb.2007.007027 PMID: 18453484

5. Meissner MH, Gloviczki P, Bergan J, Kistner RL, Morrison N, Pannier F, et al. Primary chronic venous disorders. J Vasc Surg. 2007; 46: S54–S67.

6. Lee J, Lai C, Yang W, Lee T. Increased expression of hypoxia-inducible factor-1α and metallothionein in varicocele and varicose veins. Phlebology. 2012; 27: 409–415. doi: 10.1258/phleb.2011.011051 PMID: 22345328

7. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol. 2009; 78: 539. doi: 10.1016/j.bcp.2009.04.029 PMID: 19413999

8. Ascher E, Jacob T, Hingorani A, Tsemekhin B, Gunduz Y. Expression of molecular mediators of apoptosis and their role in the pathogenesis of lower-extremity varicose veins. J Vasc Surg. 2001; 33: 1080–1086. PMID: 11331852

9. Takase S, Bergan JJ, Schmid-Schönbein G. Expression of adhesion molecules and cytokines on saphenous veins in chronic venous insufficiency. Ann Vasc Surg. 2000; 14: 427–435. PMID: 10990550

10. Li X, Jiang XY, Ge J, Wang J, Chen GJ, Xu L, et al. Aberrantly expressed lncRNAs in Primary Varicose Great Saphenous Veins. PLoS One. 2014; 9:e86156. doi:10.1371/journal.pone.0086156 PMID: 24497937

11. Clark MB, Gascoigne DK, Dinger ME, Mattick JS. IncRNAdb: a reference database for long noncoding RNAs. Nucleic Acids Res. 2011; 39, D146–D151. doi: 10.1093/nar/gkq1138 PMID: 21112873

12. Eklöf B, Rutherford RB, Bergan JJ, Carpenter PH, Gloviczki P, Kistner RL, et al. American Venous Forum International Ad Hoc Committee for Revision of the CEAP Classification. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004; 40: 1248–1252. PMID: 15622385

13. Bergan JJ, Schmid-Schönbein GW, Smith PD, Nicolaides AN, Boisserie MR, Eklöf B. Chronic venous disease. N Engl J Med. 2006; 355: 488–498. PMID: 16685552

14. Barber MR, Aldridge JR Jr, Webster RG, Magor KE. Association of RIG-I with innate immunity of ducks to influenza. Proc Natl Acad Sci U S A. 2010; 107: 5913–5918. doi:10.1073/pnas.1001755107 PMID: 20308570

15. Yin J, McLachlan C, Chaufour X, McGuire MA, White G, Turner V, et al. Growth arrest-specific gene 6 expression in proliferating rabbit vascular smooth muscle cells in vitro and in vivo. Electrophoresis. 2000; 21:3851–3856. PMID: 11271503

16. Ren F, Chen X, Hesketh J, Gan F, Huang K. Selenium promotes T-cell response to TCR-stimulation and ConA, but not PHA in primary porcinesplenocytes. PLoS One. 2012; 7:e35375. doi:10.1371/journal.pone.0035375 PMID: 22530011

17. Zeng Y, Wang W, Ma J, Wang X, Guo M, Li W. Knockdown of ZNF268, which is transcriptionally down-regulated by GATA-1, promotes proliferation of K562 cells. PLoS One. 2012; 7:e29518. doi: 10.1371/journal.pone.0029518 PMID: 22235304

18. Marks AR, Rapamycin: signaling in vascular smooth muscle. Transplant Proc. 2003; 35:231S–233S. PMID: 12742501

19. Luo M, Liu X, Zu Y, Fu Y, Zhang S, Yao L, et al. Cajanol, a novel anticancer agent from Pigeonpea [Cajanus cajan (L.) Millsp.] roots, induces apoptosis in human breast cancer cells through a
ROS-mediated mitochondrial pathway. Chem Biol Interact. 2010; 188:151–160. doi: 10.1016/j.cbi.2010.07.009 PMID: 20638373

20. Tanner FC, Boehm M, Akyürek LM, San H, Yang ZY, Tashiro J, et al. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation. 2000; 102:2022–2025. PMID: 10790340

21. Yang F, Zhang L, Huo XS, Yuan JH, Xu D, Yuan SX, et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology. 2011; 54:1679–1689. doi: 10.1002/hep.24563 PMID: 21769904

22. Cao X, Xiao H, Zhang Y, Zou L, Chu Y, Chu X. 1,5-Dicaffeoylquinic acid-mediated glutathione synthesis through activation of Nrf2 protects against OGD/reperfusion-induced oxidative stress in astrocytes. Brain Res. 2010; 1347:142–148. doi: 10.1016/j.brainres.2010.05.072 PMID: 20513363

23. Li Y, Gong H, Sun Y, Yan J, Cheng B, Zhang X, et al. Dissecting the role of disulfide bonds on the amyloid formation of insulin. Biochem Biophys Res Commun. 2011; 423:373–378. doi: 10.1016/j.bbrc.2012.05.133 PMID: 22664107

24. Mourtada-Maarabouni M, Hasan AM, Farzaneh F, Williams GT. Inhibition of human T-cell proliferation by mammalian target of rapamycin (mTOR) antagonists requires noncoding RNA growth-arrest-specific transcript 5 (GAS5). Mol Pharmacol. 2010; 78: 19–28. doi: 10.1124/mol.110.064055 PMID: 20421347

25. Mourtada-Maarabouni M, Hedge VL, Kirkham L, Farzaneh F, Williams GT. Growth arrest in human T-cells is controlled by the non-coding RNA growth-arrest-specific transcript 5 (GAS5). J Cell Sci. 2008; 121: 939–946. doi: 10.1242/jcs.024646 PMID: 18354083

26. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Canc. 2009; 9: 153–166. doi: 10.1038/nrc2602 PMID: 19238148

27. Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes. 2009; 23: 1494–1504. doi: 10.1101/gad.1800909 PMID: 19571179

28. Williams GT, Mourtada-Maarabouni M, Farzaneh F. A critical role for non-coding RNA GAS5 in growth arrest and rapamycin inhibition in human T-lymphocytes. Biochem Soc Trans. 2011; 39:482–486. doi: 10.1042/BST0390482 PMID: 21428924

29. Kino T, Hurt DE, Ichijo T, Nader N, Chrousos GP. Noncoding RNA gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor. Sci Signal. 2010; 3: ra8. doi: 10.1126/scisignal.2000551

30. Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F, Williams GT. GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene. 2009; 28: 195–208. doi: 10.1038/onc.2008.373 PMID: 18836484

31. Chiang Y, Rizzino A, Sibenaller ZA, Wold MS, Vishwanatha JK. Specific down-regulation of annexin II expression in human cells interferes with cell proliferation. Mol Cell Biochem. 1999; 199, 139–147. PMID: 10544962

32. Huang Y, Jin Y, Yan CH, Yu Y, Bai J, Chen F, et al. Involvement of Annexin A2 in p53 induced apoptosis in lung cancer. Mol Cell Biochem. 2008; 309, 117–123. PMID: 18008140

33. Chiang Y, Schneiderman MH, Vishwanatha JK. Annexin II expression is regulated during mammalian cell cycle. Cancer Res. 1993; 53:6017–6021 PMID: 8261416

34. Kumble KD, Hirota M, Pour PM, Vishwanatha JK. Enhanced levels of annexins in pancreatic carcinoma cells of Syrian hamsters and their intrapancreatic allografts. Cancer Res. 1992; 52:163–167 PMID: 1530768

35. Filipenko NR, MacLeod TJ, Yoon CS, Waisman DM. Annexin A2 is a novel RNA-binding protein. J Biol Chem. 2004; 279:8723–8731. PMID: 14672933